Compare Aurora Cannabis Inc (ACB) vs FedEx Corporation (FDX) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

FedEx trades at $312.88, down slightly by 0.04% on the day, with a bearish technical signal from moving averages. Recent quarterly earnings have consistently beaten expectations, including Q1 2026 EPS of $6.31 versus $5.91 expected. The company is streamlining operations, highlighted by the sale of its supply chain unit to CMA CGM for $1.4 billion, while maintaining solid cash flow from operations of $7.04 billion in 2025.

The outlook is mixed: analyst consensus is bullish with a $365.73 price target, but margin recovery remains uncertain. Key risks include soft shipping demand and ongoing cost pressures. Upside potential hinges on successful execution of efficiency initiatives like DRIVE and Network 2.0 to expand profitability beyond current 4.88% net margins.